SRZN News and Press, Surrozen Inc. From 12/01/21

The following slide deck was published by Surrozen, Inc. in conjunction with this event. For further details see: Surrozen (SRZN) Investor Presentation - Slideshow

The following slide deck was published by Surrozen, Inc. in conjunction with this event. For further details see: Surrozen (SRZN) Investor Presentation

Surrozen (NASDAQ:SRZN): Q3 GAAP EPS of -$0.51. Press Release Cash, cash equivalents and marketable securities were $135.4 million as of September 30, 2021, compared to $18.9 million as of June 30, 2021. For further details see: Surrozen reports Q3 results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen”...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclini...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a firesi...

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2...

Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. CEO Craig Parker, an industry veteran, joined us to discuss why there's no such thing as being too well capitalized in the biotech industry. 'We were really e...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its inflammatory bowel disease (IBD) program,...

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth “Liz” Nguyen has been appointed as Vice Pres...